(Nasdaq: CDTX), a biotechnology company developing novel anti-infectives
including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 10:20 a.m.
What would you say is the biggest barrier to implementation of novel anti-infectives
in common treatment plans and the commercial market?
- Jersey City, New Jersey-based anti-infectives
developer Scynexis, Inc.
Paul Ambrose and a leadership team that is globally recognized as a leader in anti-infective
drug development and has played a critical role in the development and approval of many anti-infectives
developed over the last decade." Under the agreement, Arsanis has granted BB100 the exclusive right to conduct further preclinical development activities on licensed mAbs, with an option to enter into an exclusive global development and commercial license.
Drug company Nuevolution AB declared on Wednesday the exercise of an option to license the right to a research programme that relates to a disease target in the therapeutic area of anti-infectives
Ricciardi also held several senior management positions at Pfizer, where she was responsible for launching three drugs and growing franchises in cardiovascular disease, arthritis/rheumatology, and anti-infectives
. She also ran the anti-infectives
commercial franchise at Pfizer and oversaw the launch of both Zithromax and Trovan.
(NYSE: PFE) has closed the acquisition of the development and commercialisation rights to Europe-based pharmaceutical company AstraZeneca's late-stage small molecule anti-infectives
business, primarily outside the United States, for USD 725m, the company said.
A decline in drug discovery is not exactly new, and it is not limited to anti-infectives
. In a global analysis published in Health Affairs in 2006, Duke University economists Henry Grabowski and Richard Yang found a reduction of about 50 percent in the annual rate of introductions of "new chemical entities" between 1982 and 2003.
The therapeutic potential of herbal-based anti-infectives
against identified respiratory bacterial pathogens was evaluated in parallel to the routine assessment of bacterial sensitivity to a panel of commercially-available antibiotics.
have the potential to deliver significant advantages over current approaches including broad, bactericidal activity against multi-resistant Gram- positive and Gram-negative pathogens.
Claris Otsuka will manufacture and distribute infusion products and solutions, anti-infectives
and volume plasma expenders primarily in Asia, the Middle East, Russia, Africa and Latin America, excluding the EU.